Dyspepsia - Dopamine.

Altered central dopamine neurotransmission in Functional Dyspepsia. I An increase and/or an altered distribution?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22541

Enrollment

Registered

2005-07-18

Start date

2004-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Single dose of 185 MBq [123I]IBZM intravenously. As controlgroup an existing file of healthy male volunteers will be used.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Nepean Dyspepsia Index (NDI) score >= 25; 2. >18 years of age.

Exclusion criteria

Exclusion criteria: 1. Use of drugs that affect gastrointestinal motility (antidepressants, opiates, NSAID’s, calcium-blockers, nitrates); 2. use of drugs that can affect binding of the radioligand to dopamine D2 receptors (neuroleptics, dopamine D2 agonists, anti-vertigo-drugs metoclopramide, alizapride); 3. IBS; 4. previous abdominal surgery; 5. history of myocardial infarct or CVA; 6. epilepsy; 7. severe liver or renal insufficience; 8. depression; 9. claustrophobia.

Contacts

Public ContactG.E.E. Boeckxstaens

Academic Medical Center (AMC), Department of Gastroenterology, C2-328, P.O. Box 22660

g.e.boeckxstaens@amc.uva.nl+31 (0)20 5667375

Outcome results